Nicotine abuse is three times more prevalent in schizophrenic over non-psychiatric populations. It has not been established whether this phenomenon is inherent to schizophrenia or an effect of chronic neuroleptic treatment. Nicotine related increases in brain dopamine are associated with its abuse. Schizophrenic patients or animals given NMDA antagonists to putatively model schizophrenia, express an enhanced dopamine response to stimulants. This response is similar in many respects to that exhibited by animals chronically treated with the neuroleptic, haloperidol. We suggest that the pathology associated with dysfunctional NMDA receptors enhances excitatory input to brain dopamine systems. While chronic antipsychotic therapy might reduce inhibitory control over dopamine. Although different in origin, these imbalances may result in a similar. Amplified, response to nicotine, It follows that the enhanced response to nicotine may be regulated by either decreasing excitatory or increasing inhibitory neurochemical activity, respective of the underlying pathophysiology. We propose to examine this hypothesis with micro PET imaging techniques and microdialysis to explore the effects of a nicotine challenge on brain dopamine in pharmacologically altered biologically states. By chronically treating rodents with the NMDA antagonist, PCP, haloperidol, or both, we intend to examine the effects of haloperidol in the absence or presence of disease on the response to nicotine. In separate groups, we propose to use additional drugs to reduce excitatory activity with the glutamate antagonist, topiramate. Or increase inhibitory activity with the GABA agonist, gamma-vinyl GABA, prior to the nicotine challenge. We hope to guide the development of novel therapies for dual-diagnosis schizophrenia.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Predoctoral Individual National Research Service Award (F31)
Project #
1F31DA015874-01
Application #
6487933
Study Section
Special Emphasis Panel (ZRG1-F01 (20))
Program Officer
Babecki, Beth
Project Start
2003-01-06
Project End
2005-01-05
Budget Start
2003-01-06
Budget End
2004-01-05
Support Year
1
Fiscal Year
2002
Total Cost
$42,106
Indirect Cost
Name
State University New York Stony Brook
Department
Other Basic Sciences
Type
Schools of Arts and Sciences
DUNS #
804878247
City
Stony Brook
State
NY
Country
United States
Zip Code
11794
Morris, Evan D; Normandin, Marc D; Schiffer, Wynne K (2008) Initial comparison of ntPET with microdialysis measurements of methamphetamine-induced dopamine release in rats: support for estimation of dopamine curves from PET data. Mol Imaging Biol 10:67-73
Frumberg, David B; Fernando, Marion S; Lee, Dianne E et al. (2007) Metabolic and behavioral deficits following a routine surgical procedure in rats. Brain Res 1144:209-18
Schiffer, Wynne K; Mirrione, Martine M; Biegon, Anat et al. (2006) Serial microPET measures of the metabolic reaction to a microdialysis probe implant. J Neurosci Methods 155:272-84
Schiffer, Wynne K; Alexoff, David L; Shea, Colleen et al. (2005) Development of a simultaneous PET/microdialysis method to identify the optimal dose of 11C-raclopride for small animal imaging. J Neurosci Methods 144:25-34
Schiffer, Wynne K; Lee, Dianne E; Brodie, Jonathan D et al. (2005) Imaging addiction with PET: is insight in sight? Drug Discov Today 10:547-62
Lee, Dianne E; Schiffer, Wynne K; Dewey, Stephen L (2004) Gamma-vinyl GABA (vigabatrin) blocks the expression of toluene-induced conditioned place preference (CPP). Synapse 54:183-5
Schiffer, Wynne K; Marsteller, Douglas; Dewey, Stephen L (2003) Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine. Psychopharmacology (Berl) 168:339-43
Schiffer, Wynne K; Azmoodeh, Manijeh; Gerasimov, Madina et al. (2003) Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens dopamine. Synapse 48:35-8